|
Match
|
Document |
Document Title |
|
|
US20120177744 |
METHOD OF USING BETA-HYDROXY-BETA-METHYLBUTYRATE FOR THE TREATMENT OF CANCER
Disclosed are methods of treating an individual having a condition characterized by an imbalance in type 1 and type 2 cytokine production, wherein the method comprises administering to the... |
|
|
US20140350041 |
Methods and Compositions for Treating a Disease Condition in a Subject
Methods for treating a disease condition in a subject are provided. The subject methods are characterizing by enhancing at least one symptom of the disease condition in a manner effective to cause... |
|
|
US20090149445 |
TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS
The present invention relates to methods of treating pathological disorders susceptible to steroid hormone nuclear receptor modulation comprising administering to a patient in need thereof an... |
|
|
US20140315957 |
ANDROGEN RECEPTOR ANTAGONISTS AND USES THEREOF
The present invention relates to novel substituted thioimidazolidinone compounds and pharmaceutical compositions comprising such compounds for treatment of androgen receptor-associated diseases or... |
|
|
US20090118169 |
NOVEL COMPOUNDS AND PHARMACEUTICAL USE THEREOF
A compound comprising the atom corresponding to N3 and the two or more atoms selected from N1, N2, N4 and N5, said atoms constitute the pharmacophore represented by the following formula: wherein... |
|
|
US20140037603 |
NUTRITIONAL COMPOSITIONS INCLUDING BRANCHED CHAIN FATTY ACIDS FOR IMPROVING GUT BARRIER FUNCTION
Nutritional compositions for improving, treating and/or preventing various medical conditions and methods of using same are provided. Such medical conditions include infection, sepsis,... |
|
|
US20080020028 |
TRANSDERMAL DOSAGE FORM COMPRISING AN ACTIVE AGENT AND A SALT AND A FREE-BASE FORM OF AN ADVERSE AGENT
This invention relates to a tamper-resistant transdermal dosage form comprising an active agent, such as an opioid, or a pharmaceutically acceptable salt thereof, a free base of an adverse agent,... |
|
|
US20090155176 |
Compositions and methods for treatment of diabetic retinopathy
The present invention provides compounds and methods for the treatment of diabetic retinopathy. In particular, LFA-1 antagonists are described herein to be used in the treatment of diabetic... |
|
|
US20140301998 |
PREPARATION CONTAINING DIOL
Disclosed is a cosmetic or dermatological formulation comprising a) at least one polyol in a concentration of from 0.1 to 20% by weight, based on the total weight of the formulation, and b) at... |
|
|
US20090042912 |
DIPHENYLIMIDAZOLYL COMPOUNDS AS INHIBITORS OF beta-SECRETASE
The present invention provides a compound of formula I and the use thereof for the therapeutic treatment, prevention or amelioration of a disease or disorder characterized by elevated β-amyloid... |
|
|
US20100323999 |
Therapeutic Molecules and Methods-1
Methods of inhibiting the cytokine or biological activity of Macrophage Migration Inhibitory Factor (MIF) comprising contacting MIF with a compound of formula (I) as defined herein, is provided.... |
|
|
US20100080762 |
SKIN CARE COMPOSITION
The present invention relates to an oral composition containing an optimal combination of nutritional ingredients at high concentrations and at optimal ratios in order to maintain and/or achieve... |
|
|
US20130158024 |
TRICYCLIC NECROSTATIN COMPOUNDS
The present invention features compounds, pharmaceutical compositions, and methods for treating trauma, ischemia, stroke, degenerative diseases associated with cellular necrosis, and other... |
|
|
US20160067257 |
SCREENING METHOD AND COMPOUNDS FOR MODULATING TELOMERASE ACTIVITY
The present invention embraces methods for identifying compounds that modulate the activity of telomerase. Compounds of the invention are identified by designing or screening for a compound which... |
|
|
US20140364439 |
MARKERS ASSOCIATED WITH CHRONIC LYMPHOCYTIC LEUKEMIA PROGNOSIS AND PROGRESSION
The present invention provides methods and devices related to markers (or biomarkers) associated with chronic lymphocytic leukemia (CLL). Examples of these markers include drivers of CLL... |
|
|
US20120277180 |
Cofactors and Methods for Use for Individuals
Provided herein are methods and systems for identifying one or more cofactors such as vitamins for individuals based on the genetic makeup of the individual by detecting the presence or absence of... |
|
|
US20160101081 |
COMPOSITIONS AND METHODS FOR ENHANCING MOBILITY OR ACTIVITY OR TREATING FRAILTY
The present invention provides a method for increasing mobility or activity in an animal or treating or preventing frailty in an animal, comprising identifying an animal with decreased mobility or... |
|
|
US20130109672 |
ACTIVATORS OF HUMAN PYRUVATE KINASE
Disclosed are pyruvate kinase M2 activators which are compounds of Formula (I), including those of Formula (II), wherein A1, A2, L, R, R1 to R3, X1 to X3, k, n, and m are as defined herein, that... |
|
|
US20090062360 |
Compounds Which Inhibit the Glycine Transporter and Uses Thereof
Compounds of formula (I) and salts and solvates thereof are provided: wherein R1 to R8 and n are defined in the description. Uses of the compounds as medicaments, and in the manufacture of... |
|
|
US20150133434 |
Compositions and Methods for Reactivating Latent Immunodeficiency Virus
The present disclosure provides compositions and methods for reactivating latent immunodeficiency vims. The methods generally involve contacting an HIV-infected cell in which HIV is latent with an... |
|
|
US20070185179 |
New compounds
The present invention relates to new compounds of formula I, where R1 and R2 are independently halo or C1-3haloalkyl, X is ethenyl or ethynyl, or a salt thereof. |
|
|
US20160060260 |
BROMODOMAIN INHIBITORS FOR TREATING DISEASE
Disclosed herein are compounds and compositions useful in the treatment of bromodomain-containing protein-mediated diseases, such as cancer, having the structure of Formula I: Methods of... |
|
|
US20100173945 |
Compounds with nootropic action, their preparation, pharmaceutical compositions containing them, and use thereof
Described herein are new bicyclic arylimidazolones having nootropic action (i.e., protecting and stimulating cerebral functions), analgesic action and anti hyperalgesic action; also described is... |
|
|
US20080206290 |
COSMETIC COMBINATION PRODUCT FOR IMPROVING APPEARANCE
A cosmetic combination product, wherein the product comprises at least two components selected from (a) one or more dietary supplements, (b) one or more cosmetic preparations for topical... |
|
|
US20130084272 |
COMPOSITIONS, KITS AND METHODS FOR NUTRITIONAL SUPPLEMENTATION WITH TWELVE CARBON CHAIN FATTY ACIDS AND TWELVE CARBON CHAIN ACYLGLYCEROLS
The present invention relates to compositions, kits and methods for the administration of compositions and kits for supplementation with twelve carbon chain fatty acids or twelve carbon chain... |
|
|
US20100267712 |
ISOINDOLINE COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES
Disclosed is a compound of Formula (I) in which W and R1-R6 are defined herein. Also disclosed is a method of treating spinal muscular atrophy, as well as methods of using such compounds to... |
|
|
US20140073604 |
Ladder-Frame Polyether Conjugates
Disclosed are compounds that are conjugates of ladder frame polyether compounds and biologically active compounds or research compounds, pharmaceutical formulations comprising the conjugates, and... |
|
|
US20110306626 |
IMIDAZOLINONE DERIVATIVES AS CGRP RECEPTOR ANTAGONISTS
The present invention is directed to imidazolinone derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which CGRP is involved, such as... |
|
|
US20150126553 |
BICYCLIC HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME
The present disclosure is directed in part to bicyclic heterocycles, such as a compound represented by formula (I) or (II) as disclosed herein, and their use in treating medical disorders, such as... |
|
|
US20130052234 |
EDIBLE STRIPS
An edible oral strip composition includes a therapeutically effective amount of active agent(s) to provide at least one effect selected from a stimulating effect, an increased physical endurance,... |
|
|
US20120322830 |
Cyclourea Compounds as Calcium Channel Blockers
The invention relates to cyclourea compounds of Formula I: or a pharmaceutically acceptable salt or solvate thereof, wherein R1-R3 and Z are defined as set forth in the specification. The... |
|
|
US20100143289 |
UMBILICAL CORD STEM CELL SECRETED PRODUCT DERIVED TOPICAL COMPOSITIONS AND METHODS OF USE THEREOF
Compositions including topical formulations comprising secreted products obtained from the culture medium of human umbilical cord stem cells and particular combinations of components therefrom are... |
|
|
US20100151045 |
COMPOSITION AND METHOD FOR REDUCING SIDE-EFFECTS OF INDOLE-3-CARBINOL AND DERIVATIVES
A method is provided for reducing side effects while treating a mammal using indole-3-carbinol, which method includes the steps of administering an effective amount of indole-3-carbinol along with... |
|
|
US20130281503 |
MODULATION OF RESPONSE REGULATORS BY IMIDAZOLE DERIVATIVES
The present disclosure provides methods and compositions useful for screening agents for activity in modulating response regulator signaling activity, which is, in turn, useful for determining... |
|
|
US20110003767 |
Inhibitors of Acetyl-CoA Carboxylase for Treatment of Neuronal Hypometabolism
This invention relates to methods of using inhibitors of the enzyme acetyl-CoA carboxylase (ACC) for the treatment, prevention, inhibition or alleviation of diseases associated with neuronal... |
|
|
US20130210875 |
Novel binding site of IKK-beta
Uses and applications derived from the discovery of a novel binding site of IKK-β, such as method of screening a therapeutic agent as drug candidate for treating cancer, inflammation, or other... |
|
|
US20050192220 |
Composition and method for potentiating drugs
A method of potentiating the activity of a drug which affects the central nervous system (CNS) comprising systemically administrating to a subject said drug together with an effective amount of a... |
|
|
US20120065210 |
SUBSTITUTED HEXAHYDROPYRROLO[1,2-C]IMIDAZOLONES
There are provided compounds of formula I or a pharmaceutically acceptable salt thereof, wherein X, Y, R1, R1′, R2, R2′, R3, R4, R5 are as defined herein. The compounds exhibit activity as... |
|
|
US20100144671 |
Compositions and Methods for Cancer Treatment
Bromoacetoxycalcidiol (B3CD), which is structurally related to calcidiol, exhibits cytotoxic and apoptotic activity toward cancer cells, including highly aggressive neuroblastoma cells. A series... |
|
|
US20080319038 |
PREVENTATIVE OR THERAPEUTIC AGENT FOR ACUTE RENAL FAILURE
An agent for prevention and treatment of acute renal failure comprising a hydantoin derivative represented by the general formula below as an active ingredient. One example of such compounds is... |
|
|
US20080076813 |
Benzene, Pyridine, and Pyridazine Derivatives
Disclosed are compounds and pharmaceutically acceptable salts of Formula I wherein A, Q1, Q2, Q3, R3, and R4 are as defined herein. Compounds of Formula I are useful in the treatment of diseases... |
|
|
US20140219995 |
INHIBITORS OF BACTERIAL TYPE III SECRETION SYSTEM
Organic compounds showing the ability to inhibit effector toxin secretion or translocation mediated by bacterial type III secretion systems are disclosed. The disclosed type III secretion system... |
|
|
US20070299119 |
Prophylactic or Therapeutic Agent for Severe Diabetic Retinopathy
A method for ameliorating severe diabetic retinopathy in a mammal comprising administering to the subject an effective amount of a compound represented by the following general formula: wherein X... |
|
|
US20080221185 |
Glyt1 Transporter Inhibitors and Uses Thereof in Treatment of Neurological and Neuropsychiatric Disorders
The invention provides a compound of formula (I) or a solvate thereof: wherein R1, R2, R3, R4, R5, R6, and n are as defined in the specification, and uses of such compounds. The compounds inhibit... |
|
|
US20140336184 |
METHOD TO ENHANCE COGNITION
The present invention concerns methods and compositions regarding suppression of double stranded RNA-activated protein kinase (PKR) to enhance cognition in an individual. In specific cases, an... |
|
|
US20120004273 |
GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS
Disclosed herein are compounds of formula (I) and: wherein: X is Ar—C(O)CH(R20)— or Ar1—NHC(O)CH2—; and Ar is:naphthyl optionally substituted with one or more groups Y;pyridyl optionally... |
|
|
US20150158862 |
1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES SUBSTITUTED WITH HETEROCYCLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS
The present invention is concerned with novel 4-substituted 1,3-dihydro-2H-benzimidazol-2-one derivatives substituted with heterocycles having formula (I) tautomers and stereoisomeric forms... |
|
|
US20090076049 |
Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1
The present invention relates to new compounds of formula (I), wherein R1 to R9 and X are as defined as in formula I, or salts, solvates or solvated salts thereof, processes for their preparation... |
|
|
US20140329858 |
Cyclic Urea Derivatives As Androgen Receptor Antagonists
The present invention is directed to compounds of formula (I) wherein R1, R2, R3, and A are defined herein. The present invention also provides for pharmaceutical compositions comprising a... |
|
|
US20090136592 |
Vitamin preparation
Two-phase preparation for temporally gradual administration comprising a) a phase (A) comprising water soluble vitamins and/or the corresponding provitamins, wherein phase (A) does not contain... |